Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation

Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the BCR::ABL1 tyrosine kinase domain (KDM) and of which the majority of which...

Descripción completa

Detalles Bibliográficos
Autores principales: Langabeer, Stephen E., Macleod, Stuart, Bhreathnach, Úna, Fadalla, Kamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139808/
https://www.ncbi.nlm.nih.gov/pubmed/37123466
http://dx.doi.org/10.1155/2023/6673144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139808/
https://www.ncbi.nlm.nih.gov/pubmed/37123466
http://dx.doi.org/10.1155/2023/6673144

Ejemplares similares